BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 26868521)

  • 1. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
    Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
    Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy.
    Walter VP; Taran FA; Wallwiener M; Hahn M; Brucker SY; Hartkopf AD
    Arch Gynecol Obstet; 2018 Mar; 297(3):785-790. PubMed ID: 29380106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
    Fehm T; Hoffmann O; Aktas B; Becker S; Solomayer EF; Wallwiener D; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(4):R59. PubMed ID: 19664291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
    Kasimir-Bauer S; Reiter K; Aktas B; Bittner AK; Weber S; Keller T; Kimmig R; Hoffmann O
    Sci Rep; 2016 May; 6():26355. PubMed ID: 27212060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
    Wimberger P; Blohmer JU; Krabisch P; Link T; Just M; Sinn BV; Simon E; Solbach C; Fehm T; Denkert C; Kühn C; Rhiem K; Tesch H; Kümmel S; Petzold A; Stötzer O; Meisel C; Kuhlmann JD; Nekljudova V; Loibl S
    Breast Cancer Res; 2023 Mar; 25(1):32. PubMed ID: 36978142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients.
    Hartkopf AD; Wallwiener M; Hahn M; Fehm TN; Brucker SY; Taran FA
    Cancer Res Treat; 2016 Jan; 48(1):115-24. PubMed ID: 25687853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
    Krishnamurthy S; Cristofanilli M; Singh B; Reuben J; Gao H; Cohen EN; Andreopoulou E; Hall CS; Lodhi A; Jackson S; Lucci A
    Cancer; 2010 Jul; 116(14):3330-7. PubMed ID: 20564098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity.
    Gröbe A; Blessmann M; Hanken H; Friedrich RE; Schön G; Wikner J; Effenberger KE; Kluwe L; Heiland M; Pantel K; Riethdorf S
    Clin Cancer Res; 2014 Jan; 20(2):425-33. PubMed ID: 24218516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX
    Aktas B; Bankfalvi A; Heubner M; Kimmig R; Kasimir-Bauer S
    Mol Clin Oncol; 2013 Nov; 1(6):1049-1054. PubMed ID: 24649291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients.
    Cabinakova M; Mikulova V; Malickova K; Vrana D; Pavlista D; Petruzelka L; Zima T; Tesarova P
    Neoplasma; 2015; 62(2):259-68. PubMed ID: 25591591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.
    Hartkopf AD; Taran FA; Wallwiener M; Hagenbeck C; Melcher C; Krawczyk N; Hahn M; Wallwiener D; Fehm T
    Breast Cancer Res; 2013; 15(5):R94. PubMed ID: 24099325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
    Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
    Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
    Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
    Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer.
    Hartkopf AD; Stefanescu D; Wallwiener M; Hahn M; Becker S; Solomayer EF; Fehm TN; Brucker SY; Taran FA
    Breast Cancer Res Treat; 2014 Sep; 147(2):345-51. PubMed ID: 25151295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients.
    Gwark S; Kim J; Kwon NJ; Kim KY; Kim Y; Lee CH; Kim YH; Kim MS; Hong SW; Choi MY; Jeon BH; Chang S; Yu J; Park JY; Lee HJ; Lee SB; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn JH; Jung KH; Kim SB; Gong GY; Ahn SH
    Sci Rep; 2020 Oct; 10(1):17466. PubMed ID: 33060768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
    Hoffmann O; Aktas B; Goldnau C; Heubner M; Oberhoff C; Kimmig R; Kasimir-Bauer S
    Anticancer Res; 2011 Oct; 31(10):3623-8. PubMed ID: 21965788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
    Bredemeier M; Kasimir-Bauer S; Kolberg HC; Herold T; Synoracki S; Hauch S; Edimiris P; Bankfalvi A; Tewes M; Kimmig R; Aktas B
    Mol Med Rep; 2017 May; 15(5):2957-2968. PubMed ID: 28358430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.